Meta Biomed Co. Ltd (059210) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Meta Biomed Co. Ltd (059210) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.05 Billion ≈ $714.42K USD) by net assets (₩121.24 Billion ≈ $82.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Meta Biomed Co. Ltd's balance sheet to measure how much of total assets are equity-financed.
Meta Biomed Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Meta Biomed Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Meta Biomed Co. Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Meta Biomed Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Meta Biomed Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Computacenter PLC
LSE:CCC
|
-0.097x |
|
Cingulate Inc
NASDAQ:CING
|
-1.434x |
|
As Commercial Industrial Company of Computers and Toys S.A.
AT:ASCO
|
0.028x |
|
Smart Digital Group Limited Ordinary Shares
NASDAQ:SDM
|
N/A |
|
Mastermyne Group Ltd
AU:MYE
|
0.071x |
|
Mesa Air Group Inc
NASDAQ:MESA
|
0.054x |
|
Pancontinental Energy NL
AU:PCL
|
-0.064x |
|
Solesence, Inc. Common Stock
NASDAQ:SLSN
|
0.061x |
Annual Cash Flow Conversion Efficiency for Meta Biomed Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Meta Biomed Co. Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Meta Biomed Co. Ltd (059210) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩93.34 Billion ≈ $63.25 Million |
₩22.63 Billion ≈ $15.34 Million |
0.242x | +72.44% |
| 2023-12-31 | ₩72.66 Billion ≈ $49.24 Million |
₩10.22 Billion ≈ $6.92 Million |
0.141x | -6.98% |
| 2022-12-31 | ₩60.59 Billion ≈ $41.06 Million |
₩9.16 Billion ≈ $6.21 Million |
0.151x | -20.83% |
| 2021-12-31 | ₩58.32 Billion ≈ $39.52 Million |
₩11.14 Billion ≈ $7.55 Million |
0.191x | +88.43% |
| 2020-12-31 | ₩47.98 Billion ≈ $32.51 Million |
₩4.86 Billion ≈ $3.29 Million |
0.101x | +88.40% |
| 2019-12-31 | ₩53.27 Billion ≈ $36.10 Million |
₩2.86 Billion ≈ $1.94 Million |
0.054x | +150.87% |
| 2018-12-31 | ₩49.97 Billion ≈ $33.86 Million |
₩-5.28 Billion ≈ $-3.58 Million |
-0.106x | -1857.36% |
| 2017-12-31 | ₩46.01 Billion ≈ $31.18 Million |
₩-248.51 Million ≈ $-168.41K |
-0.005x | -105.54% |
| 2016-12-31 | ₩51.59 Billion ≈ $34.96 Million |
₩5.03 Billion ≈ $3.41 Million |
0.098x | +0.59% |
| 2015-12-31 | ₩50.87 Billion ≈ $34.47 Million |
₩4.93 Billion ≈ $3.34 Million |
0.097x | +1547.11% |
| 2014-12-31 | ₩44.20 Billion ≈ $29.96 Million |
₩-296.24 Million ≈ $-200.76K |
-0.007x | -108.04% |
| 2013-12-31 | ₩44.54 Billion ≈ $30.18 Million |
₩3.71 Billion ≈ $2.52 Million |
0.083x | -11.04% |
| 2012-12-31 | ₩40.89 Billion ≈ $27.71 Million |
₩3.83 Billion ≈ $2.60 Million |
0.094x | -10.84% |
| 2011-12-31 | ₩39.05 Billion ≈ $26.46 Million |
₩4.10 Billion ≈ $2.78 Million |
0.105x | -- |
About Meta Biomed Co. Ltd
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone product… Read more